PANOPTES PHARMA
Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria. The development of Panoptes´ clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatmen... t is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications. Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development.
PANOPTES PHARMA
Social Links:
Industry:
Biotechnology Health Care
Founded:
2013-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.panoptes-pharma.com
Total Employee:
1+
Status:
Active
Contact:
43 676 644 7510
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Euro IPv6 1and1
Founder
Investors List
aws Gründerfonds (aws Founders Fund)
aws Gründerfonds (aws Founders Fund) investment in Seed Round - Panoptes Pharma
4SC
4SC investment in Seed Round - Panoptes Pharma
Arax Capital Partners
Arax Capital Partners investment in Seed Round - Panoptes Pharma
Official Site Inspections
http://www.panoptes-pharma.com
- Host name: 104.21.32.57
- IP address: 104.21.32.57
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Panoptes Pharma"
Panoptes Pharma - Innovationen in Ophthalmologie …
Panoptes Pharma Wir entwickeln innovative Therapien zur Behandlung von Augenkrankheiten und anderen Erkrankungen mit hohem medizinischem Bedarf. Wir sind bestrebt, die Lebensqualität von Patienten auf der ganzen Welt zu … See details»
Panoptes Pharma - Crunchbase Company Profile
Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high … See details»
Organization | Panoptes Pharma
Panoptes Pharma Report issue For profit Phase 2 Founded: Vienna Austria (2013) Status: Acquired by Eyegate Pharmaceuticals, Inc. (2020) Organization Overview First Clinical Trial … See details»
Panoptes Pharma Company Profile 2024: Valuation, Investors
Information on acquisition, funding, cap tables, investors, and executives for Panoptes Pharma. Use the PitchBook Platform to explore the full profile. See details»
Unternehmen - PANOPTES PHARMA
Über Panoptes Panoptes ist ein privates Biotech-Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien auf Basis kleiner Moleküle zur Behandlung schwerer … See details»
Panoptes Pharma GES.M.B.H - Ownership and Business Overview
Panoptes Pharma GES.M.B.H is a clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical … See details»
Panoptes Pharma GmbH - Drug pipelines, Patents, Clinical trials
Explore Panoptes Pharma GmbH with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 8 news, and 3 literature, Disease Domain:Neoplasms, Immune System … See details»
Panoptes Pharma - VentureRadar
Panoptes intends to develop PaniJect and PaniDrop up to proof-of-concept studies in different indications in ophthalmology. Panoptes Pharma is developing products based on the novel … See details»
Panoptes Pharma - 2025 Company Profile - Tracxn
May 6, 2025 Panoptes Pharma is an acqui-hired company based in Vienna (Austria), founded in 2013. It operates as a Small molecule drugs to treat eye diseases. Panoptes Pharma has … See details»
Kiora Pharmaceuticals - Craft
Kiora Pharmaceuticals (formerly known as Panoptes Pharma) is a clinical-stage biotech company focused on developing small molecule-based therapies for the treatment of severe eye … See details»
Management Team - PANOPTES PHARMA
Franz Obermayr, Ph.D Vorstandsvorsitzender Dr. Franz Obermayr ist Mitbegründer und CEO von Panoptes Pharma. Zuvor war er Leiter der klinischen Entwicklung bei Nabriva Therapeutics … See details»
EyeGate Pharma Announces Acquisition of Panoptes Pharma
Dec 21, 2020 EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel pr See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 Dr. Franz Obermayr, co-founder and Chief Executive Officer of Panoptes, and EVP Clinical Development of EyeGate, said, “This acquisition by EyeGate, a clinical-stage … See details»
Panoptes Pharma company information, funding & investors
Jul 1, 2013 Panoptes Pharma, developing innovative small molecule drugs to treat eye diseases with high unmet medical need. Here you'll find information about their funding, investors and … See details»
Kiora Pharmaceuticals Acquires Panoptes Pharma GES.M.B.H
Dec 21, 2020 Panoptes Pharma GES.M.B.H is a clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a … See details»
Über uns - PANOPTES PHARMA
Panoptes ist ein privates Biotech-Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien auf Basis kleiner Moleküle zur Behandlung schwerer … See details»
Panoptes Pharma - Funding, Financials, Valuation & Investors
Nov 2, 2015 Panoptes Pharma has raised 1 round. This was a Seed round raised on Nov 2, 2015. Panoptes Pharma is funded by 3 investors. aws Gründungsfonds and 4SC are the most … See details»
The Strategy Behind EyeGate’s Acquisition of Panoptes
With the acquisition of Vienna-based biotech Panoptes Pharma, Eye Gate Pharmaceuticals has expanded its pipeline of nonsteroidal products targeting ocular inflammation by adding … See details»
DLA Piper advises on the acquisition of Austrian biotech company ...
DLA Piper has advised Austrian biotech company Panoptes Pharma (Panoptes) on its acquisition by EyeGate Pharmaceuticals (EyeGate), a clinical stage company focused on developing … See details»
Über den Namen - PANOPTES PHARMA
Wir haben uns von Argus Panoptes inspirieren lassen, einem Riesen aus der griechischen Mythologie, der hundert Augen besaß. Er war ein sehr effektiver Wächter, da immer nur ein … See details»